Increasing prevalence of eye infections due to ocular surgical procedures is primarily shaping eye infection treatment market. A recent Future Market Insights (FMI) report forecasts that even though the eye infection treatment market would continue to experience a downtrend throughout 2020 due to COVId-19 pandemic, revenues would reach US$ 10 Bn by the end of 2030. Post-operative ocular infections remain among the most common eye infection types, says the FMI study.
Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1300
Rising Caseloads
Caseloads of ocular surgical conditions such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are growing due to sedentary lifestyle habits, and expanding geriatric cohort. According to the US statistics 2019, cataracts affect over 24 million Americans aging at least 40 years. By age 75, about half of the Americans suffer from cataract. Further, diabetic retinopathy affects nearly 7.7 million Americans aging at least 40 years. In similar fashion, there were 48,229 corneal transplants performed in the US in 2013.
Demand for eye infection treatment will continue to receive a strong impetus from increasing awareness about different eye infection types and availability of treatment, further complemented by technological advancements on ophthalmology.
Key Takeaways of Eye Infection Treatment Market Study
- Antibiotics would contribute over 55% revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
- Eye drop sales capture over 60% market share in the eye infection treatment market.
- Conjunctivitis would account for a third of eye infection treatment demand through 2030.
- Bacterial infections continue to account for over 3/5th market share.
- Hospitals and retail pharmacies collectively generate over 70% total returns to shareholders.
- Increasing rate of eye surgeries and rising usage of contact lenses continue to push North American market. European market would be upheld by the expanding geriatric pool.
Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic
The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections. According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.
Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1300
Development and Licensing Deals with Multiple Commercialization Partners
Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies. For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in Chinese market for ZERVIATE.
Know More About FMI’s Eye Infection Treatment Market Study
Eye infection treatment market, a new study from Future Market Insights, opines on eye infections treatment from 2015 – 2019 and presents demand projections from 2020 – 2030 on the basis of; drug class (antibiotics, antivirals, antifungals, antihistamines, corticosteroids, and glucocorticoids), dosage form (tablet, capsule, ophthalmic ointment, and eye drops), indication (conjunctivitis, keratitis, endophthalmitis, blepharitis, stye or sty (hordeolum), uveitis, cellulitis, and ocular herpes), causative agent (virus, bacteria, fungus, and allergens) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and drug stores) across seven prominent regions.
In light of the rise in eye infection cases, Who and other international organizations maintain their focus on raising awareness. Efforts in diagnosis and eye infection treatment are ramping up. Case in point, VISION 2020 has been established with the aim to integrate a comprehensive, sustainable, and top-notch eye care system into national healthcare infrastructure. Such initiatives are highly beneficial for countries such as India, where cataract surgeries are performed for free via government programs, aiming to cover untapped sections of the society.
The global eye infection treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Drug Class
- Antibiotics
- Antivirals
- Antifungals
- Antihistamines
- Corticosteroids
- Glucocorticoids
Dosage Form
- Tablet
- Capsule
- Ophthalmic Ointment
- Eye Drops
- Others
- Indications
- Conjunctivitis
- Keratitis
- Endophthalmitis
- Blepharitis
- Stye or Sty (Hordeolum)
- Uveitis
Causative Agents
- Virus
- Bacteria
- Fungus
- Allergens
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Regions
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Buy Complete Report @ https://www.futuremarketinsights.com/checkout/1300
Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com